Life Sciences Transactions & Regulatory

Reed Smith provides its pharmaceutical, medical device and other life sciences clients with seamless services across the United States, Europe, the Middle East and in other markets.  Our Life Sciences Team includes more than 200 attorneys and health care professionals throughout our offices.

We have the experience and multidisciplinary approach to assist you with every aspect of your business – from early stage development, corporate structure and governance, and transactions, to research, development, manufacturing, marketing and regulatory compliance.

Our Life Sciences Team combines its knowledge of the health care industry, life science product development and management requirements, regulatory demands, and litigation risks, to serve clients who develop and market drug, device, diagnostic, and biotechnology products and services. Our product liability lawyers apply their success in the courtroom to help companies assess risks up front and avoid litigation. Our regulatory attorneys advise clients on how to create the most efficient pathway through product approval and reimbursement, and across the entire product life cycle.  Our in-depth knowledge of the life sciences industry enables us to provide clients with counsel tailored to their specific operational workings and strategic business goals.

We have a long history of partnering with our clients because we understand the importance of bringing their innovations to market and protecting their commercial successes. Our reputation and track record reflect our success:

  • We represent the 10 largest global pharmaceutical manufacturers
  • Our clients include 50 of the world's leading device manufacturers, developers of cutting-edge diagnostics and biotechnology
  • We have ranked among the top U.S. law firms in number of life sciences clients represented in venture finance transactions
  • Corporate Counsel Magazine recently ranked Reed Smith as one of the top 10 law firms in the United States for quality of service, based on a survey conducted of Fortune 250 companies' in-house counsel